Organogenesis Holdings Inc. (ORGO)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Organogenesis Holdings Inc. (“Organogenesis” or the “Company”) (NASDAQ: ORGO). Investors who purchased Organogenesis shares are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/orgo.
The investigation concerns whether Organogenesis and certain of its officers and/or directors have violated federal securities laws.
On October 12, 2021, Value Investors Club issued a report alleging issues at Organogenesis, indicating that the Company has been improperly billing the federal government for $250 million annually. The Company also set the price for its new wound covering, Affinity, "exorbitantly high[,]" which Medicare reimbursed, while making the product lucrative for doctors to use through large rebates. On this news, Organogenesis’s stock price fell $1.70, or 14%, to close at $10.35 per share on October 12, 2021.
If you are aware of any facts relating to this investigation, or purchased Organogenesis shares, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.